205 related articles for article (PubMed ID: 21145196)
1. HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans.
Wadley AL; Cherry CL; Price P; Kamerman PR
J Pain Symptom Manage; 2011 Apr; 41(4):700-6. PubMed ID: 21145196
[TBL] [Abstract][Full Text] [Related]
2. Age and height predict neuropathy risk in patients with HIV prescribed stavudine.
Cherry CL; Affandi JS; Imran D; Yunihastuti E; Smyth K; Vanar S; Kamarulzaman A; Price P
Neurology; 2009 Jul; 73(4):315-20. PubMed ID: 19636052
[TBL] [Abstract][Full Text] [Related]
3. HIV neuropathy in South Africans: frequency, characteristics, and risk factors.
Maritz J; Benatar M; Dave JA; Harrison TB; Badri M; Levitt NS; Heckmann JM
Muscle Nerve; 2010 May; 41(5):599-606. PubMed ID: 20229576
[TBL] [Abstract][Full Text] [Related]
4.
Gaff J; Octaviana F; Pillay P; Mbenda HGN; Ariyanto IA; Gan JA; Cherry CL; Kamerman P; Laws SM; Price P
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936167
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic variation influences sensory neuropathy occurrence in Southern Africans treated with stavudine-containing antiretroviral therapy.
Moketla MB; Wadley AL; Kamerman P; de Assis Rosa D
PLoS One; 2018; 13(10):e0204111. PubMed ID: 30273369
[TBL] [Abstract][Full Text] [Related]
6. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.
Smyth K; Affandi JS; McArthur JC; Bowtell-Harris C; Mijch AM; Watson K; Costello K; Woolley IJ; Price P; Wesselingh SL; Cherry CL
HIV Med; 2007 Sep; 8(6):367-73. PubMed ID: 17661844
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.
Cherry CL; Skolasky RL; Lal L; Creighton J; Hauer P; Raman SP; Moore R; Carter K; Thomas D; Ebenezer GJ; Wesselingh SL; McArthur JC
Neurology; 2006 Mar; 66(6):867-73. PubMed ID: 16567704
[TBL] [Abstract][Full Text] [Related]
9. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.
Lichtenstein KA; Armon C; Baron A; Moorman AC; Wood KC; Holmberg SD;
Clin Infect Dis; 2005 Jan; 40(1):148-57. PubMed ID: 15614705
[TBL] [Abstract][Full Text] [Related]
10. Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: A 6-month follow-up study.
Pillay P; Wadley AL; Cherry CL; Karstaedt AS; Kamerman PR
J Peripher Nerv Syst; 2019 Dec; 24(4):304-313. PubMed ID: 31587421
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in CAMKK2 associate with susceptibility to sensory neuropathy in HIV patients treated without stavudine.
Gaff J; Octaviana F; Ariyanto I; Cherry C; Laws SM; Price P
J Neurovirol; 2019 Dec; 25(6):814-824. PubMed ID: 31309408
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
13. Stavudine-induced hyperlactatemia/lactic acidosis at a tertiary communicable diseases clinic in South Africa.
Hernández Pérez E; Dawood H
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(2):109-12. PubMed ID: 20484736
[TBL] [Abstract][Full Text] [Related]
14. Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.
Pahuja M; Grobler A; Glesby MJ; Karim F; Parker G; Gumede S; Naidoo K
Antivir Ther; 2012; 17(4):737-43. PubMed ID: 22414588
[TBL] [Abstract][Full Text] [Related]
15. Usage of stavudine (D4T) - a retrospective analysis in a South London hospital.
Lechelt M; McCormick S; de Ruiter A
Int J STD AIDS; 2007 Mar; 18(3):215-7. PubMed ID: 17362559
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women.
Currier JS
Clin Infect Dis; 2007 Jul; 45(2):261-2. PubMed ID: 17578789
[No Abstract] [Full Text] [Related]
17. Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
Eriksson LE; Nilsson Schönnesson L; Bratt GA
Biol Res Nurs; 2011 Jan; 13(1):89-96. PubMed ID: 19942593
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.
McGrath CJ; Njoroge J; John-Stewart GC; Kohler PK; Benki-Nugent SF; Thiga JW; Etyang A; Chung MH
J Neurovirol; 2012 Jun; 18(3):200-4. PubMed ID: 22528481
[TBL] [Abstract][Full Text] [Related]
19. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.
Osler M; Stead D; Rebe K; Meintjes G; Boulle A
HIV Med; 2010 Feb; 11(2):121-9. PubMed ID: 19702629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
